Download GlobalData’s Covid-19 Executive Briefing report
- ECONOMIC IMPACT -
Latest update: 29 June
The global economy is forecasted to return to pre-crisis levels by the end of 2021 or early 2022.
The unemployment rate in OECD nations stood at 6.5% in March 2021, down from 6.6% in Feb 2021.
According to the OECD, real GDP in the G20 area grew by 0.8% in Q1 2021 when compared to the last quarter and reached pre-pandemic level.
The consensus global real GDP growth forecast for 2021 has been revised upward from the previous estimate of 4.9% to 6.1%.
Impact of Covid-19 on equity indices
- SECTOR IMPACT: PHARMA -
Latest update: 07 July
Starting at the end of May 2020, clinical trials in India increased dramatically. India passed Iran in the total number of Covid-19 trials in October and has now surpassed China with 615 trials currently underway.
At its present rate of vaccination, the US will have been able to administer two doses of any vaccine to 75% of the entire population within 290 days, a time frame that is continually drawn out due to decreasing vaccination rates in adults.
China has administered the most single doses of Covid-19 vaccines worldwide (1,185.78 million), followed by the US (323.32 million) and India (318.03 million). However, the US has lost its position in the top ten countries globally in the vaccination rate per 1,000 population.
Gibraltar has administered the most single doses of Covid-19 vaccine per 1,000 population worldwide, followed by the United Arab Emirates and the Seychelles.
Key pharma market developments